

Body size and risk of renal cell carcinoma in the European Prospective Investigation into Cancer and Nutrition (EPIC)

Tobias Pischon, Petra H. Lahmann, Heiner Boeing, Anne Tjønneland, Jytte Halkjaer, Kim Overvad, Kerstin Klipstein-Grobusch, Jakob Linseisen, Nikolaus Becker, Antonia Trichopoulou, Vassiliki Benetou, Dimitrios Trichopoulos, Sabina Sieri, Domenico Palli, Rosario Tumino, Paolo Vineis, Salvatore Panico, Evelyn Monninkhof, Petra H.M. Peeters, H. Bas Bueno-de-Mesquita, Frederike L. Büchner, Börje Ljungberg, Göran Hallmans, Göran Berglund, Carlos Alberto Gonzalez, Miren Dorronsoro, Aurelio Barricarte Gurrea, Carmen Navarro, Carmen Martinez, J. Ramón Quirós, Andrew Roddam, Naomi Allen, Sheila Bingham, Kay-Tee Khaw, Rudolf Kaaks, Teresa Norat, Nadia Slimani, Elio Riboli

Angaben zur Veröffentlichung / Publication details:

Pischon, Tobias, Petra H. Lahmann, Heiner Boeing, Anne Tjønneland, Jytte Halkjaer, Kim Overvad, Kerstin Klipstein-Grobusch, et al. 2005. "Body size and risk of renal cell carcinoma in the European Prospective Investigation into Cancer and Nutrition (EPIC)." *International Journal of Cancer* 118 (3): 728–38. <https://doi.org/10.1002/ijc.21398>.

Nutzungsbedingungen / Terms of use:

licgercopyright

Dieses Dokument wird unter folgenden Bedingungen zur Verfügung gestellt: / This document is made available under these conditions:

Deutsches Urheberrecht

Weitere Informationen finden Sie unter: / For more information see:

<https://www.uni-augsburg.de/de/organisation/bibliothek/publizieren-zitieren-archivieren/publiz/>



Body size and risk of renal cell carcinoma in the European Prospective Investigation into Cancer and Nutrition (EPIC)

Tobias Pischon^{1*}, Petra H. Lahmann¹, Heiner Boeing¹, Anne Tjønneland², Jytte Halkjær², Kim Overvad³, Kerstin Klipstein-Grobusch¹, Jakob Linseisen⁴, Nikolaus Becker⁴, Antonia Trichopoulou⁵, Vassiliki Benetou⁵, Dimitrios Trichopoulos⁵, Sabina Sieri⁶, Domenico Palli⁷, Rosario Tumino⁸, Paolo Vineis^{9,26}, Salvatore Panico¹⁰, Evelyn Monninkhof¹¹, Petra H.M. Peeters¹¹, H. Bas Bueno-de-Mesquita¹², Frederike L. Büchner¹², Börje Ljungberg¹³, Göran Hallmans¹⁴, Göran Berglund¹⁵, Carlos Alberto Gonzalez¹⁶, Miren Dorronsoro¹⁷, Aurelio Barricarte Gurrea¹⁸, Carmen Navarro¹⁹, Carmen Martinez²⁰, J. Ramón Quirós²¹, Andrew Roddam²², Naomi Allen²³, Sheila Bingham²³, Kay-Tee Khaw²⁴, Rudolf Kaaks²⁵, Teresa Norat²⁵, Nadia Slimani²⁵ and Elio Riboli²⁵

¹Department of Epidemiology, German Institute of Human Nutrition, Potsdam-Rehbrücke, Germany

²Danish Cancer Society, Institute of Cancer Epidemiology, Copenhagen, Denmark

³Department of Clinical Epidemiology, Aalborg Hospital, Aarhus University Hospital, Aalborg, Denmark

⁴Division of Clinical Epidemiology, German Cancer Research Center, Heidelberg, Germany

⁵Department of Hygiene and Epidemiology, School of Medicine, University of Athens, Athens, Greece

⁶Epidemiology Unit, National Cancer Institute, Milan, Italy

⁷Molecular and Nutritional Epidemiology Unit, CSPO-Scientific Institute of Tuscany, Florence, Italy

⁸Cancer Registry, Azienda Ospedaliera "Civile M.P. Arezzo," Ragusa, Italy

⁹Imperial College London, London, United Kingdom

¹⁰Dipartimento di Medicina Clinica e Sperimentale, Università di Napoli, Italy

¹¹Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands

¹²Center for Nutrition and Health, National Institute of Public Health and the Environment (RIVM), Bilthoven, Netherlands

¹³Department of Surgical and Perioperative Sciences, Urology and andrology, Umeå University, Umeå, Sweden

¹⁴Department of Public Health and Clinical Medicine, Nutritional Research, Umeå University, Umeå, Sweden

¹⁵Department of Medicine, Lund University, Malmö, Sweden

¹⁶Department of Epidemiology, Catalan Institute of Oncology, IDIBELL, Barcelona, Spain

¹⁷Department of Public Health of Guipuzkoa, San Sebastian, Spain

¹⁸Sección de Vigilancia y Control Epidemiológico, Instituto de Salud Pública de Navarra, Pamplona, Spain

¹⁹Epidemiology Department, Murcia Health Council, Murcia, Spain

²⁰Escuela Andaluza de Salud Pública, Granada, Spain

²¹Health Information Unit, Public Health and Health Planning Directorate, Asturias, Spain

²²Cancer Research UK Epidemiology Unit, University of Oxford, United Kingdom

²³Dunn Human Nutrition Unit, Medical Research Council, Cambridge, United Kingdom

²⁴Department of Public Health and Primary Care, School of Clinical Medicine, University of Cambridge, Cambridge, United Kingdom

²⁵Nutrition and Hormones Group, IARC-WHO, Lyon, France

²⁶University of Torino, Torino, Italy

Previous studies suggest that obesity is related to increased risk of renal cell carcinoma (RCC); however, only a few studies report on measures of central vs. peripheral adiposity. We examined the association between anthropometric measures, including waist and hip circumference and RCC risk among 348,550 men and women free of cancer at baseline from 8 countries of the European Prospective Investigation into Cancer and Nutrition (EPIC). During 6.0 years of follow-up we identified 287 incident cases of RCC. Relative risks were calculated using Cox regression, stratified by age and study center and adjusted for smoking status, education, alcohol consumption, physical activity, menopausal status, and hormone replacement therapy use. Among women, an increased risk of RCC was conferred by body weight (relative risk [RR] in highest vs. lowest quintile = 2.13; 95% confidence interval [CI] = 1.16–3.90; *p*-trend = 0.003), body mass index (BMI) (RR = 2.25; 95% CI = 1.14–4.44; *p*-trend = 0.009), and waist (RR = 1.67; 95% CI = 0.94–2.98; *p*-trend = 0.003) and hip circumference (RR = 2.30; 95% CI = 1.22–4.34; *p*-trend = 0.01); however, waist and hip circumference were no longer significant after controlling for body weight. Among men, hip circumference (RR = 0.44; 95% CI = 0.20–0.98; *p*-trend = 0.03) was related significantly to decreased RCC risk only after accounting for body weight. Height was not related significantly to RCC risk. Our findings suggest that obesity is related to increased risk of RCC irrespective of fat distribution among women, whereas low hip circumference is related to increased RCC risk among men. Our data give further credence to public health efforts aiming to reduce the prevalence of obesity to prevent RCC, in addition to other chronic diseases.

Key words: epidemiology; kidney cancer; obesity; anthropometry; cohort study

The incidence of kidney cancer is increasing worldwide.¹ In Europe (including the Eastern European countries), there are about 81,000 new cases of kidney cancer per year, accounting for 2.9% of all cancers, and about 2.3% of all cancer deaths.² Renal cell carcinoma (RCC), which is the major type (80–90%) of kidney cancers, is a challenging diagnosis because it remains clinically occult for most of its course. Thus, 25–60% of patients with RCC are asymptomatic and the diagnosis is made incidentally from a radiologic study obtained for other reasons.^{3,4} The classical triad of flank pain, hematuria, and flank mass is uncommon (10%) and indicates advanced disease.⁵ At time of diagnosis approximately 25–30% of patients have metastatic disease, and the survival rate at advanced disease stage is poor.^{5,6} Therefore, primary prevention of RCC is of major importance.

Recent data suggest that the increasing prevalence of obesity may at least partly be responsible for the rising rates of RCC.⁷ The

*Correspondence to: Department of Epidemiology, German Institute of Human Nutrition (DIfE), Potsdam-Rehbrücke, Arthur-Scheunert-Allee 114-116, 14558 Nuthetal, Germany. Fax: +49-33200/88-721. E-mail: pischon@mail.dife.de

relationship between body weight and risk of RCC has been examined in studies based on either a population^{8–23} or hospital based^{24–28} case-control approach, and in prospective studies.^{29–39} Most of these studies, however, used self-reported body weight. Although these data are quite accurate, obese subjects are more likely to under-report whereas underweight subjects are more likely to over-report their body weight.⁴⁰ Earlier reviews suggested that the association between body weight and risk of RCC may be stronger in women than in men,^{41,42} although a recent meta-analysis found the relationship equally strong in both genders.⁴³ Differences in body fat distribution between men and women might be among the factors responsible for the differences observed in some studies. Waist and hip circumference measurements are established markers of body fat distribution in clinical and epidemiological settings^{44,45} and it has been suggested that waist circumference, as a marker of central adiposity, may be more closely related to disease incidence than body weight as a marker of obesity *per se*.^{45,46} nevertheless, we are aware of only 2 reports on the association of waist and hip circumference with risk of RCC, which have examined this relationship in the Iowa Women's Health Study.^{35,36} Similarly, there are only limited data on height as a predictor of RCC risk. Three previous studies found no such association,^{17,18,37} whereas 5 other studies found weak positive associations.^{20,21,38,39,47}

The aim of our study was to examine the association between anthropometric measures, including waist and hip circumference, and risk of RCC in participants of the European Prospective Investigation into Cancer and Nutrition (EPIC), a large European-wide cohort study. Particularly, we examined whether body fat distribution is related to risk of RCC.

Material and methods

Study population

The European Prospective Investigation into Cancer and Nutrition (EPIC) is an ongoing multicenter prospective cohort study designed primarily to investigate the relationship between nutrition and cancer. The EPIC study consists of sub cohorts recruited in 23 administrative centers in 10 European countries, including Denmark, France, Germany, Greece, Italy, the Netherlands, Norway, Spain, Sweden and the United Kingdom. The 519,978 eligible male and female participants were between 25–70 years of age at time of enrollment (1992–2000) and recruited from the general population residing in a given geographic area (*i.e.*, town or province). Exceptions were the French cohort (based on female members of a health insurance for school employees), the Utrecht cohort in the Netherlands (based on women attending breast cancer screening), the Ragusa cohort in Italy (based on blood donors and their spouses) and the Oxford cohort in the United Kingdom (based largely on vegetarian volunteers and healthy eaters). Eligible subjects were invited to participate in the study, and those who accepted gave informed consent and completed questionnaires on their diet, lifestyle and medical history. Subjects were then invited to a center to provide a blood sample and to have anthropometric measurements taken. The methods have been reported in full by Riboli *et al.*^{48,49}

Our present study is based on 495,416 participants without prevalent cancer at any site at baseline, based on the self-reported lifestyle questionnaire or based on information from the cancer registries. We excluded the French cohorts ($n = 69,023$) because they did not have information about incident kidney cancer status at the time of this analysis. Further, we excluded subjects without measured body height or weight, thus excluding the cohorts from Norway ($n = 35,956$) and an additional 8,063 participants. We further excluded subjects from the Umeå cohort ($n = 24,651$) because they did not have information on leisure time physical activity, and an additional 9,134 participants who had not filled out the dietary or nondietary questionnaires, or were in the top or bottom 1% of the ratio of energy intake to estimated energy requirement calculated from body weight, height and age⁵⁰ to

reduce the impact on the analysis of implausible extreme values; leaving 348,589 participants. For the “health-conscious” group based in Oxford (UK), linear regression models were used to predict gender- and age-specific values from subjects with measured and self-reported body measures as described previously.^{51,52}

Assessment of endpoints

Incident kidney cancer cases were identified by population cancer registries (Denmark, Italy, the Netherlands, Spain, Sweden, the United Kingdom) or by active follow-up (Germany, Greece), depending on the follow-up system in each of the participating centers. Active follow-up used a combination of methods, including health insurance records, cancer and pathology registries, and direct contact of participants or next-of-kin. Mortality data were also obtained from cancer or mortality registries at the regional or national level. Participants were followed from study entry until first kidney cancer diagnosis, death, emigration, or end of follow-up period. Mortality data were coded following the rules of the 10th revision of the International Statistical Classification of Diseases, Injuries and Causes of Death (ICD-10), and cancer incidence data following the 2nd revision of the International Classification of Diseases for Oncology (ICD-O-2). Data were coded according to ICD-10/ICD-O-2 as malignant neoplasm of the kidney except pelvis (C64); and malignant neoplasm of the renal pelvis (C65). By the end of May 2004, 365 cases of kidney cancer had been reported among the 495,416 participants in the common database at the IARC. After applying the aforementioned exclusion criteria, the dataset contained 326 cases of incident kidney cancer. We further excluded 39 subjects with renal pelvis cancer. Our final dataset for analysis included 348,550 participants with 287 cases of incident RCC.

Assessment of anthropometric data and lifestyle factors

Weight and height were measured to the nearest 0.1 kg and 0.1 or 0.5 cm, respectively, with subjects wearing no shoes, in participating centers.⁵¹ Body mass index (BMI) was calculated as weight divided by height squared (kg/m^2). Waist circumference was measured either at the narrowest torso circumference (Italy; Utrecht, the Netherlands; Denmark) or at the midpoint between the lower ribs and iliac crest (Bilthoven, the Netherlands; Potsdam, Germany; Malmö, Sweden; Oxford, UK, general population). In Spain, Greece, and Heidelberg (Germany), a combination of methods was used, although the majority of participants were measured at the narrowest circumference. Hip circumference was measured at the widest circumference (Italy; Spain; Bilthoven, the Netherlands; Greece; Malmö, Sweden) or over the buttocks (the United Kingdom; Utrecht, the Netherlands; Germany; Denmark). Results of the present analyses for waist and hip circumference were similar for the different assessment methods. In our dataset, waist and hip circumference measurements were missing in 3,858 and 6,378 participants, respectively. These participants were excluded for analyses on these variables. For the present study, body weight and waist and hip circumference were corrected to reduce heterogeneity due to protocol differences in clothing worn during measurement, as described in detail elsewhere.⁵¹

Recreational and household activity was computed as average metabolic equivalent-hours (MET-hr), based on the types and durations of activities separately reported for summer and winter on the baseline questionnaires. The reported activities included walking, cycling, gardening, sports and exercise, housework, do-it-yourself activities, stair-climbing and vigorous recreational activity. Each type of activity was assigned a specific MET-value according to the Compendium of Physical Activities by Ainsworth *et al.*⁵³ Occupational activity was coded as sedentary occupation, standing occupation, manual work, heavy manual work, unemployed, or missing, as reported on the questionnaire. To create a variable that encompasses total physical activity subjects were cross-classified based on gender-specific quartiles of recreational and household activity and on categories of occupational work,

TABLE I – COHORT CHARACTERISTICS¹

Country	Cohort size (n)	Age (mean, years)	Follow-up (mean, years)	Person-years	% Women	RCC cases (n)
Italy	44,221	50.5	5.9	261,460	68.6	43
Spain	39,609	49.2	6.7	265,020	62.2	24
United Kingdom	73,553	49.3	5.4	396,150	69.3	38
Netherlands	37,378	48.9	6.2	232,079	73.5	29
Greece	25,450	53.1	3.7	94,315	58.6	6
Germany	49,053	50.6	5.8	286,429	56.5	65
Sweden	24,268	58.0	7.6	185,218	57.7	32
Denmark	55,018	56.7	6.7	369,144	52.2	50
Total	348,550	51.6	6.0	2,089,813	62.8	287

¹The European Prospective Investigation into cancer and Nutrition (EPIC).

TABLE II – CHARACTERISTICS OF MALE STUDY PARTICIPANTS IN THE EPIC BY BMI¹

	Quintile of BMI (kg/m ²)				
	1	2	3	4	5
BMI, kg/m ²					
Range	<23.6	23.6–25.3	25.4–27.0	27.1–29.3	≥29.4
Mean	22.0	24.5	26.3	28.1	32.0
n	25,943	25,953	25,963	25,943	25,943
Age, years	50.4	52.7	53.2	53.8	54.0
Hypertension, %	10.8	15.4	18.9	23.2	32.1
Diabetes, %	2.3	2.6	3.0	4.1	6.4
Alcohol, g/d	20.0	21.2	22.2	23.3	24.7
Weight, kg	68.2	75.5	80.1	85.1	95.6
Height, cm	175.9	175.2	174.5	173.8	172.7
Waist circumference, cm	84.0	89.9	94.0	98.5	107.4
Hip circumference, cm	94.4	98.0	100.4	103.1	108.8
Waist-hip-ratio	0.89	0.92	0.94	0.96	0.99
Smoking status ² , %					
Never	33.4	32.1	30.3	27.9	26.5
Past	29.9	36.0	39.1	41.1	42.0
Current	34.8	30.4	29.0	29.5	30.0
Education ² , %					
No school degree or primary school	21.7	24.8	28.5	35.4	42.6
Technical or professional school	24.4	25.2	25.7	25.2	23.7
Secondary school	15.6	16.0	15.2	13.9	12.9
University degree	34.6	30.8	27.5	22.7	17.8
Physical activity ² , %					
Inactive	19.7	20.4	20.1	20.0	19.9
Moderately inactive	28.8	28.1	28.5	28.9	29.1
Moderately active	35.7	35.0	35.6	35.2	36.2
Active	13.1	13.9	13.2	13.6	13.1

¹Numbers are means. All values except age, BMI and number of subjects are age-standardized. ²Numbers do not add up to 100% due to missing values.

and coded as inactive, moderately inactive, moderately active, active and missing.

Information on sociodemographic and lifestyle characteristics and medical history was obtained from standardized questionnaires at study entry.⁴⁸ Women were classified according to menopausal status at enrollment based on an algorithm that accounts for complete and combined information on menstrual status/history, type of menopause (natural, bi-/unilateral oophorectomy, hysterectomy), use of oral contraceptives and menopausal hormones.⁵⁴

Statistical analyses

We analyzed the association between anthropometric variables and risk of RCC separately for men and women by calculating relative risks as incident rate ratios using Cox proportional hazard models. Age was used as the underlying time variable in the counting process with entry and exit time defined as the subject's age at recruitment and age at RCC diagnosis or censoring, respectively. Subjects were categorized separately into quintiles based on the anthropometric variables over the entire male or female cohort, respectively. We also ran additional analyses by categorizing participants into pre-defined established categories for BMI (<25, 25 to <30 and ≥30 kg/m²) and waist circumference (<94, 94 to <102 and ≥102 cm in men; and <80, 80 to <88 and ≥88

in women).⁴⁴ Models were stratified by age at recruitment and by study center to be less sensitive against violations of the proportional hazards assumption. We further adjusted the analysis for smoking status (never, past, current or unknown), education (no school degree or primary school, technical or professional school, secondary school, university degree or unknown), alcohol consumption (g/d, continuously), and physical activity (inactive, moderately inactive, moderately active, active, missing). In women, we also adjusted for menopausal status (premenopausal, perimenopausal, naturally postmenopausal, surgically postmenopausal or missing) and current hormone replacement therapy (no, yes or unknown). Analyses on weight, waist and hip circumference, and waist-hip ratio were also adjusted for body height. In additional models we also adjusted corresponding models for body weight to examine the association of fat distribution patterns with risk of RCC independent of body weight. We also ran additional models that adjusted for total energy intake; however, because the overall results did not substantially change we decided not to include energy intake in our analysis. To test for linear trend across categories we used the median anthropometric variable within quintiles as a continuous variable. In separate analyses we included the body size measures as continuous variables into the models to estimate the relative risk of RCC per increase in anthropometric variables. We checked the proportional hazard assumption by adding

TABLE III – CHARACTERISTICS OF FEMALE STUDY PARTICIPANTS IN THE EPIC BY BMI¹

	Quintile of Body Mass Index (kg/m ²)				
	1	2	3	4	5
BMI, kg/m ²					
Range	<21.8	21.8–23.7	23.8–25.9	26.0–28.9	≥29.0
Mean	20.4	22.8	24.9	27.4	32.9
<i>n</i>	43,760	43,760	43,764	43,760	43,761
Age, years	46.0	49.5	51.7	53.4	54.1
Hypertension, %	9.9	12.9	16.4	21.2	31.9
Diabetes, %	1.0	1.1	1.6	2.7	5.3
Alcohol, g/d	9.6	9.4	8.7	7.6	5.8
Weight, kg	54.7	60.8	65.3	71.0	83.6
Height, cm	163.7	163.0	162.0	160.9	159.3
Waist circumference, cm	69.8	74.6	78.9	84.6	95.7
Hip circumference, cm	92.4	96.8	100.2	104.5	113.9
Waist-hip-ratio	0.76	0.77	0.79	0.81	0.84
Smoking status ² , %					
Never	49.9	51.0	52.6	56.5	62.6
Past	23.8	25.7	24.8	22.6	19.6
Current	25.9	22.7	22.0	20.3	16.9
Education ² , %					
No school degree or primary school	16.4	21.1	28.3	37.6	48.3
Technical or professional school	29.3	29.3	28.0	25.6	22.0
Secondary school	20.6	20.3	19.3	17.5	14.2
University degree	28.5	24.1	19.7	14.8	10.4
Menopausal status ² , %					
Premenopausal	35.2	35.1	34.9	34.8	35.0
Perimenopausal	11.9	12.1	11.8	11.8	11.4
Postmenopausal	46.3	45.7	45.7	44.9	44.5
Surgical postmenopausal	2.5	2.8	3.2	3.9	4.7
HRT use among postmenopausal women ² , %					
No	71.7	72.7	75.0	79.1	85.1
Yes	25.8	25.1	22.9	19.2	13.4
Physical activity ² , %					
Inactive	18.7	17.6	15.9	13.4	11.1
Moderately inactive	31.4	30.0	28.1	26.7	25.3
Moderately active	39.3	41.2	44.6	48.9	52.8
Active	9.3	9.8	9.9	9.4	9.4

¹Numbers are means. All values except age, BMI and number of subjects are age-standardized.–²Numbers do not add up to 100% due to missing values.

an interaction term of the main exposure variable with time to each model. The interaction term was non-significant at the 5%-level in any of these models, indicating that there is no evidence of an increasing or decreasing trend over time in the hazard ratio. Differences for the associations of body size with risk of RCC between men and women were assessed by χ^2 -test using the heterogeneity statistics based on the inverse variance method.⁵⁵

All *p*-values presented are 2-tailed and *p*-values <0.05 were considered statistically significant. Analyses were carried out using SAS 9.1 (SAS Institute, Cary, NC) and STATA 8.2 (STATA Corporation, College Station, TX).

Results

Overall, 348,550 participants were followed for an average 6.0 ± 1.6 years, for a total of 2,089,813 person-years (Table I). During follow-up, 287 incident cases (132 female) of RCC were identified within this cohort. Mean age at inclusion was 51.6 years; 62.8% of participants were female.

Tables II and III show the characteristics of the EPIC participants by BMI quintiles for men and women, respectively. Participants in the higher BMI categories were older and reported more frequently a history of hypertension and diabetes. Alcohol consumption was positively related to BMI in men but inversely related in women. Both men and women in the higher BMI categories were less likely to be current smokers and had a lower education level. Among postmenopausal women, the use of hormone replacement therapy was more common among leaner women.

Tables IV and V show the relative risk of RCC by quintiles of anthropometric variables, in men and women, respectively. Height, weight, BMI and waist circumference were not significantly related to risk of RCC in men (Table IV). There was an inverse association between increasing hip circumference and RCC risk, which became stronger after adjusting for body weight, such that the relative risk in the highest vs. lowest quintile of hip circumference was 0.44 (95% CI = 0.20–0.98; *p*-trend = 0.03). Waist-hip ratio was also positively associated with RCC risk, although this was not significant at the 5% level. The relative risk in the highest vs. lowest quintile of waist-hip ratio was 1.86 (95% CI = 0.97–3.56; *p*-trend = 0.07) in the multivariable model after accounting for body weight.

Among women, body weight and BMI were positively related to risk of RCC and women in the highest vs. the lowest quintile of body weight had a 2-fold increased risk after multivariable adjustment (relative risk [RR] = 2.13; 95% confidence interval [CI] = 1.16–3.90; *p*-trend = 0.003; Table V). The association with BMI was similar to that for body weight; the relative risk of women in the highest vs. lowest quintile of BMI was 2.25 (95% CI = 1.14–4.44; *p*-trend = 0.009). These associations were only slightly attenuated when the models were further adjusted for waist-hip ratio (RR comparing highest vs. lowest quintile for weight = 1.90; 95% CI = 1.00–3.63; *p*-trend = 0.02; RR for BMI = 1.99; 95% CI = 0.97–4.07; *p*-trend = 0.04). Waist and hip circumference were each significantly related to increased risk of RCC, but after adjustment for body weight these associations were attenuated and no longer significant at the 5% level. Height was not related to RCC risk in women.

TABLE IV - RR OF RENAL CELL CARCINOMA ACROSS QUINTILES OF ANTHROPOMETRIC MEASURES IN MEN OF THE EPIC

Body measure	Quintile					p-trend
	1	2	3	4	5	
Height, cm	<168.0	168.0-172.4	172.5-176.1	176.2-180.4	≥180.5	
No. cases	32	29	27	36	31	
Crude RR (95% CI) ¹	1	0.92 (0.55-1.54)	0.89 (0.52-1.52)	1.27 (0.76-2.10)	1.30 (0.76-2.23)	0.19
MV adjusted RR (95% CI) ²	1	0.93 (0.56-1.56)	0.91 (0.53-1.55)	1.29 (0.77-2.16)	1.33 (0.77-2.30)	0.17
Weight, kg	<71.0	71.0-76.9	77.0-82.6	82.7-89.9	≥90.0	
No. cases	27	25	37	28	38	
Crude RR (95% CI) ¹	1	0.93 (0.54-1.61)	1.32 (0.80-2.19)	1.01 (0.59-1.73)	1.36 (0.82-2.26)	0.20
MV adjusted RR (95% CI) ³	1	0.91 (0.53-1.59)	1.29 (0.77-2.18)	0.98 (0.56-1.73)	1.28 (0.73-2.25)	0.35
BMI, kg/m ²	<23.6	23.6-25.3	25.4-27.0	27.1-29.3	≥29.4	
No. cases	29	35	23	28	40	
Crude RR (95% CI) ¹	1	1.05 (0.64-1.73)	0.65 (0.37-1.13)	0.79 (0.46-1.33)	1.12 (0.68-1.84)	0.77
MV adjusted RR (95% CI) ²	1	1.07 (0.65-1.77)	0.67 (0.39-1.18)	0.84 (0.49-1.43)	1.22 (0.74-2.03)	0.51
Waist, cm	<86.3	86.3-91.9	92.0-96.9	97.0-102.9	≥103.0	
No. cases	23	31	30	30	41	
Crude RR (95% CI) ¹	1	1.11 (0.65-1.92)	0.94 (0.54-1.63)	0.96 (0.55-1.67)	1.24 (0.73-2.11)	0.48
MV adjusted RR (95% CI) ³	1	1.13 (0.66-1.95)	0.96 (0.55-1.67)	0.96 (0.55-1.69)	1.27 (0.74-2.19)	0.45
MV + body weight adjusted RR (95% CI) ³	1	1.14 (0.64-2.00)	0.96 (0.52-1.79)	0.97 (0.49-1.94)	1.28 (0.55-3.03)	0.67
Hip, cm	<95.5	95.5-98.9	99.0-101.9	102.0-105.9	≥106.0	
No. cases	37	32	23	26	34	
Crude RR (95% CI) ¹	1	0.77 (0.48-1.23)	0.61 (0.36-1.04)	0.67 (0.40-1.12)	0.89 (0.54-1.45)	0.59
MV adjusted RR (95% CI) ³	1	0.72 (0.45-1.17)	0.56 (0.32-0.95)	0.60 (0.35-1.02)	0.77 (0.46-1.29)	0.33
MV + body weight adjusted RR (95% CI) ³	1	0.63 (0.38-1.04)	0.44 (0.25-0.80)	0.43 (0.23-0.81)	0.44 (0.20-0.98)	0.03
WHR	<0.888	0.888-0.922	0.923-0.952	0.953-0.989	≥0.990	
No. cases	19	30	28	32	43	
Crude RR (95% CI) ¹	1	1.23 (0.69-2.20)	1.07 (0.59-1.92)	1.15 (0.65-2.06)	1.53 (0.88-2.67)	0.15
MV adjusted RR (95% CI) ³	1	1.28 (0.72-2.28)	1.13 (0.62-2.04)	1.25 (0.70-2.24)	1.72 (0.97-3.02)	0.06
MV + body weight adjusted RR (95% CI) ³	1	1.31 (0.73-2.35)	1.17 (0.64-2.16)	1.32 (0.71-2.44)	1.86 (0.97-3.56)	0.07

¹Crude model is derived from Cox regression using age as the underlying time variable, and stratified by center and age at recruitment. ²Multivariable models for height and BMI are based on the crude model with additional adjustment for smoking status, education, alcohol consumption and physical activity. ³Multivariable models for weight, waist, hip and WHR are based on the crude model with additional adjustment for age, smoking status, education, alcohol consumption, physical activity and body height. Test for linear trend across categories is based on the median anthropometric variable within quintiles as a continuous variable.

TABLE V - RR OF RENAL CELL CARCINOMA ACROSS QUINTILES OF ANTHROPOMETRIC MEASURES IN WOMEN OF THE EPIC

Body measure	Quintile					p-trend
	1	2	3	4	5	
Height, cm						
No. cases	<156.0	156.0–159.9	160.0–163.4	163.5–167.6	≥167.7	
Crude RR (95% CI) ¹	25	30	29	30	18	
MV adjusted RR (95% CI) ²	1	1.22 (0.71–2.10)	1.09 (0.62–1.90)	1.22 (0.69–2.14)	0.93 (0.48–1.78)	0.90
Weight, kg						
No. cases	<57.4	57.4–62.6	62.7–67.9	68.0–75.5	≥75.6	
Crude RR (95% CI) ¹	18	21	21	30	42	
MV adjusted RR (95% CI) ³	1	1.07 (0.57–2.01)	1.01 (0.53–1.90)	1.36 (0.75–2.46)	1.97 (1.12–3.47)	0.003
BMI, kg/m ²						
No. cases	<21.8	21.8–23.7	23.8–25.9	26.0–29.0	≥29.1	
MV adjusted RR (95% CI) ²	12	22	24	37	37	0.003
Waist, cm						
No. cases	<71.0	71.0–75.9	76.0–81.9	82.0–89.9	≥90.0	
Crude RR (95% CI) ¹	1	1.48 (0.73–3.00)	1.36 (0.68–2.74)	1.99 (1.03–3.85)	2.26 (1.16–4.41)	0.006
MV adjusted RR (95% CI) ²	1	1.48 (0.73–3.01)	1.39 (0.69–2.80)	1.99 (1.03–3.88)	2.25 (1.14–4.44)	0.009
Hip, cm						
No. cases	19	14	19	35	45	
Crude RR (95% CI) ¹	1	0.67 (0.33–1.34)	0.78 (0.41–1.49)	1.21 (0.68–2.15)	1.73 (0.98–3.04)	0.002
MV adjusted RR (95% CI) ³	1	0.67 (0.33–1.34)	0.78 (0.41–1.50)	1.19 (0.66–2.13)	1.67 (0.94–2.98)	0.003
MV + body weight adjusted RR (95% CI) ³	1	0.65 (0.32–1.33)	0.75 (0.38–1.50)	1.11 (0.56–2.22)	1.50 (0.64–3.53)	0.11
WHR						
No. cases	<94.0	94.0–98.0	98.1–102.8	102.9–107.9	≥108.0	
Crude RR (95% CI) ¹	15	26	23	31	37	
MV adjusted RR (95% CI) ³	1	1.72 (0.91–3.26)	1.32 (0.68–2.55)	1.75 (0.93–3.28)	2.24 (1.21–4.15)	0.01
MV + body weight adjusted RR (95% CI) ³	1	1.76 (0.92–3.35)	1.38 (0.71–2.68)	1.81 (0.96–3.43)	2.30 (1.22–4.34)	0.01
WHR						
No. cases	<0.74	0.74–0.76	0.77–0.79	0.80–0.84	≥0.85	
Crude RR (95% CI) ¹	19	15	22	36	40	
MV adjusted RR (95% CI) ³	1	0.64 (0.32–1.27)	0.77 (0.41–1.45)	1.21 (0.68–2.14)	1.37 (0.77–2.43)	0.03
MV + body weight adjusted RR (95% CI) ³	1	0.62 (0.32–1.24)	0.74 (0.39–1.38)	1.14 (0.64–2.02)	1.26 (0.71–2.25)	0.06
	1	0.60 (0.30–1.19)	0.68 (0.36–1.27)	0.98 (0.54–1.79)	1.01 (0.54–1.89)	0.33

¹Crude model is derived from Cox regression using age as the underlying time variable, and stratified by center and age at recruitment. ²Multivariable models for height and BMI are based on the crude model with additional adjustment for smoking status, education, alcohol consumption, physical activity, menopausal status and HRT use. ³Multivariable models for weight, waist, hip, and WHR are based on the crude model with additional adjustment for age, smoking status, education, alcohol consumption, physical activity, body height, menopausal status and HRT use. Test for linear trend across categories is based on the median anthropometric variable within quintiles as a continuous variable.




FIGURE 1 – Multivariable adjusted relative risk of renal cell carcinoma across body mass index categories in men (a) and women (b) participating in the European Prospective Investigation into Cancer and Nutrition. Dots and numbers = RR; error bars = 95% CI. RR derived from Cox regression using age as the underlying time variable, stratified by center and age at recruitment, and additional adjustment for smoking status, education, alcohol consumption, and physical activity. In women additionally adjusted for menopausal status and HRT use.

We further divided participants into established categories for BMI and waist circumference (Figs. 1,2). In these analyses, obese women (BMI = ≥ 30 kg/m²) had a 1.68-fold increased risk (95% CI = 1.03–2.75) of RCC compared to non-overweight women (BMI = < 25 kg/m²). The RR for women with a waist circumference ≥ 88 cm compared to women with a waist circumference < 80 cm was 1.80 (95% CI = 1.18–2.75). In contrast, BMI and waist circumference were not associated with RCC risk in men (Figs. 1,2).

We also examined the relative risk of RCC in extreme categories of BMI by comparing subjects in the highest 10% of BMI (BMI = ≥ 31.2 kg/m² in men and ≥ 31.8 kg/m² in women, respectively) with those in the lowest 25% (BMI = < 24.1 kg/m² in men and 22.4 kg/m² in women, respectively). In these analyses, the multivariable adjusted RR of RCC was 1.08 (95% CI = 0.56–2.06) for men and 2.63 (95% CI = 1.19–5.79) for women.

We further evaluated the association of body size with risk of RCC between men and women (Table VI). This analysis sug-

gested differences between both genders, although most *p*-values for heterogeneity did not reach statistical significance. For example, 5 kg higher weight or 5 cm larger waist circumference were significantly related to 10 or 12% higher risk of RCC, respectively, in women but not in men (*p* for difference between men and women = 0.15 and 0.10, respectively).

We did not detect significant differences in the association of anthropometric measures with risk of RCC when we stratified our analysis by geographic regions in Northern (Sweden, Denmark), Central (United Kingdom, Netherlands, Germany), and Southern (Italy, Spain, Greece) Europe, although sample size limited the interpretability of this analysis (data not shown).

When we repeated our analysis with exclusion of RCC cases occurring during the first 2 years of follow-up, leaving 107 cases among men and 83 cases among women, we found similar results compared to those presented in Tables IV and V. In the multivariable-adjusted analysis, the relative risk in the highest compared to lowest quintile for height was 1.44 (95% CI = 0.75–2.75; *p*-trend =




FIGURE 2 – Multivariable adjusted relative risk of renal cell carcinoma across waist circumference categories men (a) and women (b) of the European Prospective Investigation into Cancer and Nutrition. Dots and numbers = RR; error bars = 95% CI. RR derived from Cox regression using age as the underlying time variable, stratified by center and age at recruitment, and additional adjustment for smoking status, education, alcohol consumption, physical activity, and body height. In women additionally adjusted for menopausal status and HRT use.

0.13) among men and 1.30 (95% CI = 0.56–3.05; p -trend = 0.68) among women, for weight was 1.58 (95% CI = 0.80–3.12; p -trend = 0.18) among men and 2.20 (95% CI = 1.00–4.84; p -trend = 0.008) among women, and for BMI 1.46 (95% CI = 0.79–2.68; p -trend = 0.18) among men and 2.17 (95% CI = 0.98–4.80; p -trend = 0.02) among women. Not controlling for body weight the relative risk in extreme quintiles for waist circumference was 1.29 (95% CI = 0.67–2.49; p -trend = 0.42) among men and 1.82 (95% CI = 0.89–3.73; p -trend = 0.003) among women, for hip circumference 0.96 (95% CI = 0.51–1.82; p -trend = 0.95) among men and 2.00 (95% CI = 0.94–4.24; p -trend = 0.009) among women, for waist-hip ratio 1.46 (95% CI = 0.74–2.87, p -trend = 0.23) among men and 1.28 (95% CI = 0.60–2.74; p -trend = 0.11) among women.

Discussion

In this large prospective cohort study of 348,550 Europeans significant associations between body size and risk of RCC were

found. Among women, all measures of obesity, including BMI, body weight, waist and hip circumference were related to an increased risk of RCC. In contrast, among men, fat distribution pattern, specifically low hip circumference, was predictive of RCC.

Several previous studies have examined the association between body weight and risk of kidney cancer;^{8–39} however, we are aware of only 2 reports from the Iowa Women's Health Study that examined the relationship of waist and hip circumference with risk of RCC.^{35,36}

The pathophysiology underlying the association between obesity and increased RCC risk is unclear although several mechanisms may be possible. Adiposity is related to increased levels of insulin and insulin-like growth factor 1 (IGF-1), which are known to have cancer promoting effects.^{56–59} Obesity is also related to an increased risk of hypertension and diabetes, both of which are risk factors for RCC.^{37,60,61} Finally, obesity may also increase risk of RCC through elevation of estrogen levels,⁶² or through increased

TABLE VI—MULTIVARIABLE ADJUSTED RR OF RENAL CELL CARCINOMA PER INCREASE IN ANTHROPOMETRIC VARIABLES IN MEN AND WOMEN OF THE EPIC¹

	Men		Women		<i>P</i> _{heterogeneity}
	RR (95% CI)	<i>p</i>	RR (95% CI)	<i>p</i>	
Height, per 5 cm	1.12 (0.99–1.27)	0.08	1.03 (0.89–1.19)	0.70	0.39
Weight, per 5 kg	1.02 (0.95–1.10)	0.55	1.10 (1.02–1.18)	0.009	0.15
BMI, per 1 kg/m ²	1.01 (0.97–1.06)	0.54	1.05 (1.01–1.09)	0.01	0.19
Waist, per 5 cm	1.02 (0.94–1.11)	0.66	1.12 (1.04–1.21)	0.005	0.10
Weight adjusted	0.98 (0.82–1.17)	0.81	1.09 (0.94–1.27)	0.24	0.37
Hip, per 5 cm	0.94 (0.82–1.07)	0.36	1.11 (1.01–1.21)	0.04	0.04
Weight adjusted	0.75 (0.60–0.93)	0.01	0.95 (0.77–1.17)	0.63	0.13
Waist-hip-ratio, per 0.1	1.26 (0.96–1.65)	0.09	1.29 (1.02–1.63)	0.03	0.90
Weight adjusted	1.31 (0.95–1.79)	0.10	1.18 (0.90–1.54)	0.24	0.62

¹Multivariable models are derived from Cox regression using age as the underlying time variable, stratified by center and age at recruitment, and additional adjustment for smoking status, education, alcohol consumption and physical activity. Multivariable models for weight, waist, hip and WHR are also adjusted for height. In women models are additionally adjusted for menopausal status and HRT use.

glomerular filtration rate and renal plasma flow.⁶³ The changes in physiological functions that accompany obesity depend to a certain extent on the regional adipose tissue distribution. In this context, intra-abdominal visceral obesity is related to elevated blood pressure and insulin levels, insulin resistance, and dyslipidemia, and several studies show that upper-body fat distribution is independently associated with a higher risk of developing diabetes and cardiovascular disease (reviewed by Pi-Sunyer).⁶⁴ The role of body fat distribution for RCC development is less clear. In the Iowa Women's Health Study,^{35,36} the relative risk of kidney cancer in the highest compared to the lowest quintile of body weight was 3.55 (95% CI = 1.92–6.57) whereas for waist-hip ratio it was 3.37 (95% CI = 1.81–6.27), suggesting an equally strong association for both measurements.

We found measures of obesity, including weight, BMI, and waist and hip circumference to be related to RCC in women. The association between waist and hip circumference and risk were substantially attenuated after controlling for body weight, however, indicating that fat distribution does not predict RCC risk in women beyond adiposity in general. In line with these arguments, waist-hip ratio, as a measure of fat distribution, was only weakly related to RCC risk in women. In contrast, the association of body weight and BMI with risk of RCC was only modestly attenuated when waist-hip ratio was taken into account, suggesting that general adiposity is a more important determinant of risk, irrespective of body fat distribution in women. Among men, hip circumference was inversely related to RCC risk after accounting for body weight, suggesting that in men, the fat distribution pattern, and particularly hip circumference may be more predictive of RCC risk than obesity per se. This may reflect a substitution effect with more subcutaneous peripheral and less visceral abdominal fat; however, waist circumference itself was not significantly related to RCC risk in our analysis. In fact, several recent prospective studies suggest that large hip circumference may independently convey protection toward development of diabetes, cardiovascular disease, and early mortality.^{65–67} The biological mechanisms are unknown, but may include a larger muscle mass in the gluteofemoral region, which may relate to increased insulin sensitivity and improved metabolic state,⁶⁸ or more fat depots in the lower body region (particularly of subcutaneous location), which may protect the liver from fatty acid overload.^{69,70} Data on cancer endpoints in relation to hip circumference are scarce.^{54,71} Finally, the combination of highly correlated measures may lead to imprecision and instability of the effect estimates; however, the CI in our analysis did not substantially change when we combined hip circumference with body weight.

Height has been related to several types of cancer, including colon, breast, pancreatic and prostate cancer.^{54,72} Tallness may reflect exposure to insulin and insulin-like growth factor 1 (IGF-1) in pre-adulthood and may thereby relate to increased cancer

risk.^{56,57} It was estimated recently that 18% of total cancers are attributable to factors related to tallness.⁷² There is only a limited number of previous studies on height as a predictor of RCC risk. Three previous studies found no such association,^{17,18,37} whereas 5 other studies found weak positive associations.^{20,21,38,39,47} In our present study, height was not significantly related to increased risk of RCC. In summary, it seems fair to conclude that height is not related to a substantially increased risk of RCC.

Our study has several strengths and limitations. Among the strengths are the prospective design and the large sample size that included several European countries. Further, all body measures were assessed directly at baseline, in contrast to self-reported data used in the majority of previous studies. In contrast to several previous studies the present study distinguished between cancers of the renal parenchyma and the renal pelvis having different etiology and pathophysiology. Residual confounding by geographic differences is unlikely because we found similar results for Northern, Central and Southern Europe (data not shown). RCC is a rare disease compared to other types of cancer, like colorectal, prostate or breast cancer, which limits the number of cases and may thus limit the power to detect associations in our analysis. We found differences in the associations of body size measures and risk of RCC between men and women; however, the tests for heterogeneity between genders did not reach statistical significance. It is not clear whether these differences reflect true biological diversity between men and women or are due to random fluctuation. Several previous studies have found stronger results for the association between weight and risk of RCC in women compared to men.^{15–18,27} In contrast, a meta-analysis suggested that the association between obesity and risk of RCC may be equally strong between genders and argued that the discrepancies may be due to the fact that “women tend to be more obese” than men, meaning that the highest BMI category for women usually consists of more obese individuals than the highest category for men, resulting in a higher observed RR.⁴³ However, our risk estimates did not substantially change when we excluded participants with a BMI <20 and >35 from our analysis (data not shown). Further, the gender differences persisted when BMI was used on a continuous scale. Despite exclusion of participants with reported cancers at baseline we cannot exclude the possibility that some subjects had underlying yet undiagnosed RCC. Results did not appreciably change when we excluded subjects with a follow-up time of <2 years.

In conclusion, in this European study measures of obesity were associated with increased risk of RCC irrespective of the fat distribution pattern among women, and measures of abdominal obesity, particularly a low hip circumference, were associated with increased RCC risk among men. Our data give further credence to public health efforts aiming to reduce the prevalence of obesity to prevent RCC, in addition to other chronic diseases.

Acknowledgements

We thank Bertrand Hemon, Ellen Kohlsdorf, Wolfgang Bernigau, and Dr. Steffen Weikert for data coding, and all participants in EPIC for their invaluable contribution to the study. The work described in our study was carried out with the financial support of the "Europe Against Cancer" Programme of the European Commission (SANCO); Deutsche Krebshilfe; German Cancer Research Center; German Federal Ministry of Education and Research; Danish Cancer Society; Health Research Fund (FIS) of the Spanish Ministry of Health (Network RCEP C03/09); the Spanish Regional Governments of Andalusia, Asturias, Basque

Country, Murcia and Navarra; ISCIII, Red de Centros RCEP, C03/09; Cancer Research UK; Medical Research Council, UK; the Stroke Association, UK; British Heart Foundation; Department of Health, UK; Food Standards Agency, UK; the Wellcome Trust, UK; Greek Ministry of Health; Greek Ministry of Education; Italian Association for Research on Cancer; Italian National Research Council; Dutch Ministry of Public Health, Welfare and Sports; National Cancer Registry and the Regional Cancer Registries Amsterdam, East and Maastricht of the Netherlands; World Cancer Research Fund (WCRF); Swedish Cancer Society; Swedish Scientific Council; Regional Government of Skåne, Sweden.

References

- Mathew A, Devesa SS, Fraumeni JF Jr, Chow WH. Global increases in kidney cancer incidence, 1973–1992. *Eur J Cancer Prev* 2002;11:171–8.
- Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2000: cancer incidence, mortality and prevalence worldwide. version 1.0. IARC CancerBase No. 5. vol. 2004. Lyon: IARC Press, 2001.
- Jayson M, Sanders H. Increased incidence of serendipitously discovered renal cell carcinoma. *Urology* 1998;51:203–5.
- Luciani LG, Cestari R, Tallarigo C. Incidental renal cell carcinoma: age and stage characterization and clinical implications: study of 1092 patients (1982–1997). *Urology* 2000;56:58–62.
- Curti BD. Renal cell carcinoma. *JAMA* 2004;292:97–100.
- Sant M, Aareleid T, Berrino F, Bielska Lasota M, Carli PM, Faivre J, Grosclaude P, Hedelin G, Matsuda T, Moller H, Moller T, Verdecchia A, et al. EUROCARE-3: survival of cancer patients diagnosed 1990–94—results and commentary. *Ann Oncol* 2003;14(Suppl):v61–118.
- Bergstrom A, Pisani P, Tenet V, Wolk A, Adami HO. Overweight as an avoidable cause of cancer in Europe. *Int J Cancer* 2001;91:421–30.
- McLaughlin JK, Mandel JS, Blot WJ, Schuman LM, Mehl ES, Fraumeni JF Jr. A population-based case-control study of renal cell carcinoma. *J Natl Cancer Inst* 1984;72:275–84.
- Yu MC, Mack TM, Hanisch R, Cicioni C, Henderson BE. Cigarette smoking, obesity, diuretic use, and coffee consumption as risk factors for renal cell carcinoma. *J Natl Cancer Inst* 1986;77:351–6.
- Asal NR, Geyer JR, Risser DR, Lee ET, Kadamani S, Cherng N. Risk factors in renal cell carcinoma. II. Medical history, occupation, multivariate analysis, and conclusions. *Cancer Detect Prev* 1988;13:263–79.
- Kadamani S, Asal NR, Nelson RY. Occupational hydrocarbon exposure and risk of renal cell carcinoma. *Am J Ind Med* 1989;15:131–41.
- Maclure M, Willett W. A case-control study of diet and risk of renal adenocarcinoma. *Epidemiology* 1990;1:430–40.
- Partanen T, Heikkilä P, Hernberg S, Kauppinen T, Moneta G, Ojajarvi A. Renal cell cancer and occupational exposure to chemical agents. *Scand J Work Environ Health* 1991;17:231–9.
- McCredie M, Stewart JH. Risk factors for kidney cancer in New South Wales, Australia. II. Urologic disease, hypertension, obesity, and hormonal factors. *Cancer Causes Control* 1992;3:323–31.
- McLaughlin JK, Gao YT, Gao RN, Zheng W, Ji BT, Blot WJ, Fraumeni JF Jr. Risk factors for renal-cell cancer in Shanghai, China. *Int J Cancer* 1992;52:562–5.
- Kreiger N, Marrett LD, Dodds L, Hilditch S, Darlington GA. Risk factors for renal cell carcinoma: results of a population-based case-control study. *Cancer Causes Control* 1993;4:101–10.
- Mellemaard A, Lindblad P, Schlehofer B, Bergstrom R, Mandel JS, McCredie M, McLaughlin JK, Niwa S, Odaka N, Pommer W. International renal-cell cancer study. III. Role of weight, height, physical activity, and use of amphetamines. *Int J Cancer* 1995;60:350–4.
- Chow WH, McLaughlin JK, Mandel JS, Wacholder S, Niwa S, Fraumeni JF Jr. Obesity and risk of renal cell cancer. *Cancer Epidemiol Biomarkers Prev* 1996;5:17–21.
- Yuan JM, Castella JE, Gago-Dominguez M, Ross RK, Yu MC. Hypertension, obesity and their medications in relation to renal cell carcinoma. *Br J Cancer* 1998;77:1508–13.
- Lindblad P, Wolk A, Bergstrom R, Persson I, Adami HO. The role of obesity and weight fluctuations in the etiology of renal cell cancer: a population-based case-control study. *Cancer Epidemiol Biomarkers Prev* 1994;3:631–9.
- Mellemaard A, Engholm G, McLaughlin JK, Olsen JH. Risk factors for renal-cell carcinoma in Denmark. III. Role of weight, physical activity and reproductive factors. *Int J Cancer* 1994;56:66–71.
- Boeing H, Schlehofer B, Wahrendorf J. Diet, obesity and risk for renal cell carcinoma: results from a case control-study in Germany. *Z Ernahrungswiss* 1997;36:3–11.
- Hiatt RA, Tolan K, Quesenberry CP, Jr. Renal cell carcinoma and thiazide use: a historical, case-control study (California, USA). *Cancer Causes Control* 1994;5:319–25.
- Wynder EL, Mabuchi K, Whitmore WF Jr. Epidemiology of adenocarcinoma of the kidney. *J Natl Cancer Inst* 1974;53:1619–34.
- Goodman MT, Morgenstern H, Wynder EL. A case-control study of factors affecting the development of renal cell cancer. *Am J Epidemiol* 1986;124:926–41.
- Talamini R, Baron AE, Barra S, Bidoli E, La Vecchia C, Negri E, Serraino D, Franceschi S. A case-control study of risk factor for renal cell cancer in northern Italy. *Cancer Causes Control* 1990;1:125–31.
- Benhamou S, Lefant MH, Ory-Paoletti C, Flamant R. Risk factors for renal-cell carcinoma in a French case-control study. *Int J Cancer* 1993;55:32–6.
- Muscat JE, Hoffmann D, Wynder EL. The epidemiology of renal cell carcinoma. A second look. *Cancer* 1995;75:2552–7.
- Lew EA, Garfinkel L. Variations in mortality by weight among 750,000 men and women. *J Chronic Dis* 1979;32:563–76.
- Whittemore AS, Paffenbarger RS Jr, Anderson K, Lee JE. Early precursors of urogenital cancers in former college men. *J Urol* 1984;132:1256–61.
- Mellemaard A, Moller H, Olsen JH, Jensen OM. Increased risk of renal cell carcinoma among obese women. *J Natl Cancer Inst* 1991;83:1581–2.
- Finkle WD, McLaughlin JK, Rasgon SA, Yeoh HH, Low JE. Increased risk of renal cell cancer among women using diuretics in the United States. *Cancer Causes Control* 1993;4:555–8.
- Gamble JF, Pearlman ED, Nicolich MJ. A nested case-control study of kidney cancer among refinery/petrochemical workers. *Environ Health Perspect* 1996;104:642–50.
- Heath CW Jr, Lally CA, Calle EE, McLaughlin JK, Thun MJ. Hypertension, diuretics, and antihypertensive medications as possible risk factors for renal cell cancer. *Am J Epidemiol* 1997;145:607–13.
- Prineas RJ, Folsom AR, Zhang ZM, Sellers TA, Potter J. Nutrition and other risk factors for renal cell carcinoma in postmenopausal women. *Epidemiology* 1997;8:31–6.
- Nicodemus KK, Sweeney C, Folsom AR. Evaluation of dietary, medical and lifestyle risk factors for incident kidney cancer in postmenopausal women. *Int J Cancer* 2004;108:115–21.
- Chow WH, Gridley G, Fraumeni JF Jr, Jarvholm B. Obesity, hypertension, and the risk of kidney cancer in men. *N Engl J Med* 2000;343:1305–11.
- van Dijk BA, Schouten LJ, Kiemeny LA, Goldbohm RA, van den Brandt PA. Relation of height, body mass, energy intake, and physical activity to risk of renal cell carcinoma: results from the Netherlands cohort study. *Am J Epidemiol* 2004;160:1159–67.
- Bjorge T, Tretli S, Engeland A. Relation of height and body mass index to renal cell carcinoma in two million Norwegian men and women. *Am J Epidemiol* 2004;160:1168–76.
- Kuskowska-Wolk A, Karlsson P, Stolt M, Rossner S. The predictive validity of body mass index based on self-reported weight and height. *Int J Obes* 1989;13:441–53.
- Wolk A, Lindblad P, Adami HO. Nutrition and renal cell cancer. *Cancer Causes Control* 1996;7:5–18.
- McLaughlin JK, Lipworth L. Epidemiologic aspects of renal cell cancer. *Semin Oncol* 2000;27:115–23.
- Bergstrom A, Hsieh CC, Lindblad P, Lu CM, Cook NR, Wolk A. Obesity and renal cell cancer—a quantitative review. *Br J Cancer* 2001;85:984–90.
- Obesity: preventing and managing the global epidemic. Report of a WHO consultation. *World Health Organ Tech Rep Ser* 2000;894:1–253.
- Overweight, obesity, and health risk. National Task Force on the Prevention and Treatment of Obesity. *Arch Intern Med* 2000;160:898–904.
- Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: executive summary. Expert Panel on the Identification, Evaluation, and Treatment of Overweight in Adults. *Am J Clin Nutr* 1998;68:899–917.

47. Tulinius H, Sigfusson N, Sigvaldason H, Bjarnadottir K, Tryggvadottir L. Risk factors for malignant diseases: a cohort study on a population of 22,946 Icelanders. *Cancer Epidemiol Biomarkers Prev* 1997; 6:863–73.
48. Riboli E, Hunt KJ, Slimani N, Ferrari P, Norat T, Fahey M, Charrondiere UR, Hemon B, Casagrande C, Vignat J, Overvad K, Tjonneland A, et al. European Prospective Investigation into Cancer and Nutrition (EPIC): study populations and data collection. *Public Health Nutr* 2002;5:1113–24.
49. Riboli E, Kaaks R. The EPIC Project: rationale and study design. European Prospective Investigation into Cancer and Nutrition. *Int J Epidemiol* 1997;26(Suppl):S6–14.
50. Bingham SA, Gill C, Welch A, Day K, Cassidy A, Khaw KT, Sneyd MJ, Key TJ, Roe L, Day NE. Comparison of dietary assessment methods in nutritional epidemiology: weighed records v. 24 h recalls, food-frequency questionnaires and estimated-diet records. *Br J Nutr* 1994;72:619–43.
51. Haftenberger M, Lahmann PH, Panico S, Gonzalez CA, Seidell JC, Boeing H, Giurdanella MC, Krogh V, Bueno-de-Mesquita HB, Peeters PH, Skeie G, Hjartaker A, et al. Overweight, obesity and fat distribution in 50- to 64-year-old participants in the European Prospective Investigation into Cancer and Nutrition (EPIC). *Public Health Nutr* 2002;5:1147–62.
52. Spencer EA, Appleby PN, Davey GK, Key TJ. Validity of self-reported height and weight in 4808 EPIC-Oxford participants. *Public Health Nutr* 2002;5:561–5.
53. Ainsworth BE, Haskell WL, Leon AS, Jacobs DR Jr, Montoye HJ, Sallis JF, Paffenbarger RS Jr. Compendium of physical activities: classification of energy costs of human physical activities. *Med Sci Sports Exerc* 1993;25:71–80.
54. Lahmann PH, Hoffmann K, Allen N, Van Gils CH, Khaw KT, Tehard B, Berrino F, Tjonneland A, Bigaard J, Olsen A, Overvad K, Clavel-Chapelon F, et al. Body size and breast cancer risk: findings from the European prospective investigation into cancer and nutrition (EPIC). *Int J Cancer* 2004;111:762–71.
55. Takkouche B, Cadarso-Suarez C, Spiegelman D. Evaluation of old and new tests of heterogeneity in epidemiologic meta-analysis. *Am J Epidemiol* 1999;150:206–15.
56. Aaronson SA. Growth factors and cancer. *Science* 1991;254:1146–53.
57. Kaaks R, Lukanova A. Energy balance and cancer: the role of insulin and insulin-like growth factor-I. *Proc Nutr Soc* 2001;60:91–106.
58. Cheung CW, Vesey DA, Nicol DL, Johnson DW. The roles of IGF-I and IGFBP-3 in the regulation of proximal tubule, and renal cell carcinoma cell proliferation. *Kidney Int* 2004;65:1272–9.
59. Kellner M, von Eye Corleta H, Muhlhofer A, Capp E, Mosthaf L, Bock S, Petrides PE, Haring HU. Insulin- and insulin-like growth-factor-I receptor tyrosine-kinase activities in human renal carcinoma. *Int J Cancer* 1995;62:501–7.
60. Schlehofer B, Pommer W, Møllegaard A, Stewart JH, McCredie M, Niwa S, Lindblad P, Mandel JS, McLaughlin JK, Wahrendorf J. International renal-cell-cancer study. VI. the role of medical and family history. *Int J Cancer* 1996;66:723–6.
61. Lindblad P, Chow WH, Chan J, Bergstrom A, Wolk A, Gridley G, McLaughlin JK, Nyren O, Adami HO. The role of diabetes mellitus in the aetiology of renal cell cancer. *Diabetologia* 1999;42:107–12.
62. Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. *Nat Rev Cancer* 2004;4:579–91.
63. Hall JE, Brands MW, Henegar JR. Mechanisms of hypertension and kidney disease in obesity. *Ann N Y Acad Sci* 1999;892:91–107.
64. Pi-Sunyer FX. The obesity epidemic: pathophysiology and consequences of obesity. *Obes Res* 2002;10(Suppl):97S–104S.
65. Heitmann BL, Frederiksen P, Lissner L. Hip circumference and cardiovascular morbidity and mortality in men and women. *Obes Res* 2004;12:482–7.
66. Lissner L, Bjorkelund C, Heitmann BL, Seidell JC, Bengtsson C. Larger hip circumference independently predicts health and longevity in a Swedish female cohort. *Obes Res* 2001;9:644–6.
67. Bigaard J, Frederiksen K, Tjonneland A, Thomsen BL, Overvad K, Heitmann BL, Sorensen TI. Waist and hip circumferences and all-cause mortality: usefulness of the waist-to-hip ratio? *Int J Obes Relat Metab Disord* 2004;28:741–7.
68. Seidell JC, Han TS, Feskens EJ, Lean ME. Narrow hips and broad waist circumferences independently contribute to increased risk of non-insulin-dependent diabetes mellitus. *J Intern Med* 1997; 242:401–6.
69. Snijder MB, Dekker JM, Visser M, Yudkin JS, Stehouwer CD, Bouter LM, Heine RJ, Nijpels G, Seidell JC. Larger thigh and hip circumferences are associated with better glucose tolerance: the Hoorn study. *Obes Res* 2003;11:104–11.
70. Friedman J. Fat in all the wrong places. *Nature* 2002;415(6869): 268–9.
71. Morimoto LM, White E, Chen Z, Chlebowski RT, Hays J, Kuller L, Lopez AM, Manson J, Margolis KL, Muti PC, Stefanick ML, McTiernan A. Obesity, body size, and risk of postmenopausal breast cancer: the Women's Health Initiative (United States). *Cancer Causes Control* 2002;13:741–51.
72. Giovannucci E, Rimm EB, Liu Y, Willett WC. Height, predictors of C-peptide and cancer risk in men. *Int J Epidemiol* 2004;33:217–25.